Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
用户7nEFK6amBq5Y
5个月前
184
10
已完结
1. 系统已在2025-03-12 15:48:06对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.ejca.2024.114296
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0959804924009523
其他信息:
出版社: Elsevier BV
作者: Martin Reck; Tudor-Eliade Ciuleanu; Michael Schenker; Stephanie Bordenave; Manuel Cobo; Oscar Juan-Vidal; Niels Reinmuth; Eduardo Richardet; Enriqueta Felip; Juliana Menezes; Ying Cheng; Hideaki Mizutani; Bogdan Zurawski; Aurelia Alexandru; David P. Carbone; Shun Lu; Thomas John; Takekazu Aoyama; Diederik J. Grootendorst; Nan Hu; Laura J. Eccles; Luis G. Paz-Ares
